| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GW843682X | CTRPv2 | pan-cancer | AAC | 0.057 | 0.09 |
| mRNA | YK 4-279 | CTRPv2 | pan-cancer | AAC | 0.052 | 0.09 |
| mRNA | FQI-1 | CTRPv2 | pan-cancer | AAC | 0.074 | 0.1 |
| mRNA | BRD-A02303741 | CTRPv2 | pan-cancer | AAC | 0.061 | 0.1 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.055 | 0.1 |
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | 0.061 | 0.1 |
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | -0.18 | 0.1 |
| mRNA | CR-1-31B | CTRPv2 | pan-cancer | AAC | 0.049 | 0.1 |
| mRNA | BRD-K66453893 | CTRPv2 | pan-cancer | AAC | 0.048 | 0.1 |
| mRNA | selumetinib:navitoclax (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.055 | 0.1 |